Skip to content

To explore the value of TCR fingerprint in screening and predicting the efficacy of peg-interferon therapy in patients with chronic hepatitis B

To explore the value of TCR fingerprint in screening and predicting the efficacy of peg-interferon therapy in patients with chronic hepatitis B

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300071650
Enrollment
Unknown
Registered
2023-05-22
Start date
2023-05-22
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatitis B virus

Interventions

NAs-treated group (adding on PEG-IFN treatment):N/A
naive group (PEG-IFN treatment):N/A

Sponsors

General Hospital of Eastern Theater Command
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: positive-HBsAg last for more than 6 months prior to enrollment; HBV DNA=10000 IU/ml; HBsAg=5000 IU/ml(Architect HBsAg assay), especially HBsAg=1500 IU/ml; HBeAg=100 S/CO or undetected; alanine aminotransferase (ALT)=5 upper limitation of normal (ULN); age from 10 to 60 years; males and females all can be accepted; no cirrhosis except compensated cirrhosis (Child A).

Exclusion criteria

Exclusion criteria: autoimmune diseases; severe metabolic diseases; history of severe psychiatric disease, especially depression; severe complications in any organ; pregnant during treatment or will be pregnant in 6 months after treatment; lactating women; evidence of carcinoma; and any other situations that cant use PEG-IFN according to the illustration; treatment duration didnt reach 48 weeks or didn’t do tests at observed time.

Design outcomes

Primary

MeasureTime frame
TCR;HBsAg;

Countries

China

Contacts

Public ContactHao Kunyan

General Hospital of Eastern Theater Command

kunyanhao198415@163.com+86 25 8086 4058

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026